Opening https://www.businesswire.com/news/home/20240508670229/en/Bayer-to-unveil-late-breaking-data-from-Phase-III-OASIS-1-and-2-for-elinzanetant-in-the-treatment-of-vasomotor-symptoms-associated-with-menopause